Summary by Moomoo AI
Aethlon Medical, Inc. filed an Amendment No. 1 to its Annual Report on Form 10-K for the fiscal year ended March 31, 2024. The amendment includes information on executive changes, with James B. Frakes appointed as Interim CEO and CFO, replacing Charles J. Fisher, Jr., M.D. who departed in November 2023. The company also disclosed details of its executive compensation and equity awards.The filing revealed updated director compensation, with non-employee directors receiving both cash retainers and restricted stock units. The company's Amended and Restated Non-Employee Director Compensation Policy provides for initial and annual equity grants to eligible directors. Aethlon also disclosed its executive employment agreements, including severance provisions and equity incentives.The amendment included information on related party transactions, notably the separation agreement with former CEO Dr. Fisher. Aethlon's Audit Committee is responsible for approving related person transactions. The company also reported on its principal accountant fees and services, with Baker Tilly billing $489,196 for fiscal year 2024, primarily for audit and tax services.
